Virupaksha Organics Limited IPO

01At a glance

What the company does — makes small-molecule APIs, intermediates and key starting materials, and offers contract development and manufacturing; it had 54 products — 23 APIs and 31 intermediates — at March 2025 (DRHP p.27). Analgesics, anti-histamines and anti-fungals were 88.27% of FY25 revenue (DRHP p.30).

Who pays it — drug makers in India and abroad; the top ten customers were 41.87% of FY25 revenue, and sales outside India 17.49% (DRHP p.30, DRHP p.148).

Why it is raising money — ₹3,600.00 million for capacity expansion at its expansion units, ₹1,950.00 million to repay borrowings, and the rest for general purposes (DRHP p.28).

How fast it has grown — revenue from ₹6,448 million in FY23 to ₹7,660 million in FY24 and ₹8,117 million in FY25 (DRHP p.27).

The one thing to understand — a growing API maker with regulatory exposure at its plants. The pollution board alleged non-compliance with the Water Act at Unit 3 and Unit 6 and issued closure directions; the document lists this among its top four risks (DRHP p.31).

02The business, in plain words

An API maker runs chemical reactions in reactors to produce the active ingredients that formulation companies turn into medicines, and sells them to those companies; it also makes products to other companies' specifications.

A formulation company making a painkiller needs its active ingredient → it orders from Virupaksha → Virupaksha synthesises it in its reactors and tests it → it ships the batch with quality documents and is paid on credit.

The company had 223 reactors and 988 kilolitres of capacity in FY25 (DRHP p.148).

Earnings equation: Profit ≈ kilograms sold × (price − raw-material and processing cost) − interest. Gross margin was 45.48% and EBITDA margin 17.77% in FY25 (DRHP p.148).

03Where the money comes from

Source: DRHP p.30, DRHP p.148.

04The growth record

Source: DRHP p.29, DRHP p.148, DRHP p.373.

05What the growth is made of

Domestic API sales. The share of revenue from India rose from 67% to 83%, while contract manufacturing fell from 19% to 4% and exports from 33% to 17% (DRHP p.148). Growth slowed to 6% in FY25 (our arithmetic, DRHP p.148). The company recently acquired Progenerics Pharma and Oxygenta Pharmaceutical (DRHP p.31).

06Earnings quality

Operating cash flow of ₹2,327.03 million over FY23 to FY25 exceeded profit of ₹1,954.86 million (our arithmetic, DRHP p.29, DRHP p.373). Investing outflows were ₹3,491.70 million over the same period, including ₹1,847.17 million in FY25 (our arithmetic, DRHP p.373). There are no auditor qualifications not given effect in the restated accounts (DRHP p.30).

07The balance sheet

Source: DRHP p.29, DRHP p.148.

Net worth rose ₹1,813 million in FY25 against profit of ₹787 million; financing inflows were ₹1,023.02 million (our arithmetic, DRHP p.29, DRHP p.373). Share capital rose from ₹124.80 million in FY23 to ₹410.22 million (DRHP p.29).

08What the money is for

Source: DRHP p.28.

09Who is selling

Nobody. The issue is a fresh issue only, of up to ₹7,400 million (DRHP p.27).

10Promoters

The promoters are Chandra Mouliswar Reddy Gangavaram, Balasubba Reddy Mamilla, Chandrasekhar Reddy Gangavaram, Vedavathi Gangavaram, Kondapalli Sandeep Reddy, Kotla Suraj Reddy, Mamilla Nagarjun Reddy, Gangavaram Sri Lakshmi and G Sri Vidya (DRHP p.27). An executive engineer of the Karnataka Industrial Areas Development Board at Bidar filed a first information report on 15 February 2024 against Balasubba Reddy Mamilla, promoter and whole-time director, under penal-code sections and the Prevention of Damage to Public Property Act (DRHP p.30).

11Who already owns it

Source: DRHP p.28, DRHP p.29. The last row is our arithmetic. The promoters hold 49.61% between them (our arithmetic); promoter-group and other holdings were not read for this study.

12What changed just before the IPO

• Pollution board — closure directions for Unit 3 and Unit 6 (DRHP p.31).
• Acquisitions — Progenerics Pharma and Oxygenta Pharmaceutical (DRHP p.31).
• Equity — net worth up ₹1,813 million in FY25 (DRHP p.29).
• Mix — exports and contract manufacturing down as shares of revenue (DRHP p.148).

13Capacity and expansion

988 kilolitres of reactor capacity across 223 reactors in FY25 (DRHP p.148). The proceeds fund ₹3,600 million of expansion (DRHP p.28).

14Market size and industry structure

The F&S report cited in the offer document projects India's API market to grow from USD 4.1 billion in 2024 to USD 6.0 billion by 2029, and the Indian contract development and manufacturing market from USD 5.5 billion to USD 10.5 billion (DRHP p.27). Those projections are F&S's, and newboard has not tested them.

15Competitive position

What the document claims, and what it rests on:

• R&D-driven development of APIs and intermediates (DRHP p.27).
• Breadth — 54 products across APIs and intermediates (DRHP p.27).

Against that: dependence on three therapy areas, regulatory inspections, pollution-board action, hazardous processes and integration of acquisitions (DRHP p.30, DRHP p.31).

16Peers the company named

The peer table was not read for this study.

No P/E is possible for the company until a price band is set.

17Risks, in plain words

• Three therapy areas. 88% of revenue (DRHP p.30).
• Pollution board. Closure directions at two units (DRHP p.31).
• Inspections. Regulatory and customer audits (DRHP p.30).
• Customers. Ten customers were 42% of revenue (DRHP p.30).
• Acquisitions. Integration of two recent purchases (DRHP p.31).

18Litigation and regulatory matters

Source: DRHP p.30.

19Related-party transactions

Not read in detail for this study.

20What the offer document does not say

In the sections read for this study, the document does not give:

• Whether Units 3 and 6 are operating, and what share of output they produce, in the pages read.
• What the KIADB complaint alleges, in the pages read.
• What was paid for Progenerics and Oxygenta, in the pages read.
• Who subscribed to new shares in FY25, and at what price, in the pages read.
• The price band, lot size or issue dates, which is normal at DRHP stage.

21Five questions for management

1. Are Units 3 and 6 running, and what do the pollution board's closure directions require?
2. What does the KIADB complaint against Balasubba Reddy Mamilla concern?
3. Why did contract manufacturing fall from 19% to 4% of revenue?
4. What were the acquisitions of Progenerics and Oxygenta for, and what did they cost?
5. Why did export share halve between FY23 and FY25?

1Sources and cited facts

This study was read from 1 document the company filed. The 28 figures it cites are listed under the document each came from, with the page and the sentence as printed.